The CEA Registry Blog

By CEA Registry Team on 3/21/2017 10:22 AM
This week we highlighted findings from recently published cost-effectiveness studies:
 
  • Biomarker analysis potentially cost-saving diagnostic method for Alzheimer’s disease: When at least 1 in 11 patients has Alzheimer’s disease in a population, biomarker analysis is likely cost-effective. In areas where the prevalence of Alzheimer’s disease may be low, biomarker analysis is unlikely to be cost-effective at a willingness-to-pay threshold of $50,000/QALY gained. (6)
  • Review of cervical cancer screening methods cost-effectiveness in low- and middle-income countries: HPV testing and visual inspection with acetic acid (VIA) are more cost-effective screening methods than cytology for cervical cancer in low- and middle-income countries. (7)
  • Cost-effectiveness of identifying persons for early-stage chronic kidney disease screening: Chronic kidney disease risk scores may allow clinicians to cost-effectively identify a larger population for screening and potentially identify people at earlier stages of the disease than current practices. (13)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published March 13-17, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
 
1: Akers L, Rohde P, Stice E, Butryn ML, Shaw H. Cost-effectiveness of achieving  clinical improvement with a dissonance-based eating disorder prevention program. Eat Disord. 2017 Mar 13:1-10. PMID: 28287919.
 
2: Camacho EM, Ntais D, Jones S, Riste L, Morriss R, Lobban F, Davies LM. Cost-effectiveness of structured group psychoeducation versus unstructured group support for bipolar disorder: Results from a multi-centre pragmatic randomized controlled trial. J Affect Disord. 2017 Mar 15;211:27-36. PMID: 28086146.
 
3: Estades-Rubio FJ, et al. Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid.Int J Mol Sci. 2017 Mar 17;18(3). PMID: 28304363.
 
4: Hauser RG, Campbell SM, Brandt CA, Wang S. Cost-Effectiveness Study of Criteria to Screen Herpes Simplex PCR Tests from Cerebrospinal Fluid. J Clin Microbiol. 2017 Mar 15. PMID: 28298450.
 
5: Jansen JP, et al. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. J Med Econ. 2017 Mar 15:1-27. PMID: 28294642.
 
6: Lee SA, Sposato LA, Hachinski V, Cipriano LE. Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2017 Mar 16;9(1):18. PubMed PMID: 28302164.
 
7: Mezei AK, et al. Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review. Int J Cancer. 2017 Mar 15. PMID: 28297074.
 
8: Rodin D, et al. Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):709-717. PMID: 28244405.
 
9: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, Sill B, Hede S, Yuan Y, Gorsh B. Cost-effectiveness of combination daclatasvir-sofosbuvir for the treatment of genotype 3 chronic hepatitis c infection in the United States. J Med Econ. 2017 Mar 15:1-20. PMID: 28294645.
 
10: Walsh EK, Hansen CR, Sahm LJ, Kearney PM, Doherty E, Bradley CP. Economic impact of medication error: a systematic review. Pharmacoepidemiol Drug Saf. 2017 Mar 13. PMID: 28295821.
 
11: Wan XM, Peng LB, Ma JA, Li YJ. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. Cancer. 2017 Mar 16. PMID: 28301684.
 
12: Watt M, Dinh A, Le Monnier A, Tilleul P. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France. J Med Econ. 2017 Mar 16:1-9. PMID: 28299963.
 
13: Yarnoff BO, Hoerger TJ, Simpson SK, Leib A, Burrows NR, Shrestha SS, Pavkov
ME; Centers for Disease Control and Prevention CKD Initiative. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol. 2017 Mar 13;18(1):85. PMID: 28288579.

 

By CEA Registry Team on 3/13/2017 4:27 PM
 This week we highlighted findings from recently published cost-effectiveness studies:
  • Exercise program during cancer treatment cost-effective for colon cancer, but not breast cancer patients: An exercise intervention begun early after diagnosis was found to be more beneficial and less costly for colon cancer patients than for breast cancer patients in the Netherlands. (3)
  • Review of influenza immunization programs evaluate cost-effectiveness of universal versus targeted approaches: A universal approach over a targeted approach was found to be more cost-effective with an emphasis on vaccinating high-risk individuals. (6)
  • Different non-pharmacological treatments reviewed for knee osteoarthritis: A review of 11 non-pharmacological treatments for knee osteoarthritis in the UK found transcutaneous electrical nerve Stimulation (TENS) to be the most cost-effective. Among only higher quality RCTs reviewed, acupuncture was  cost-effective. (9)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published March 6-10, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Buti M, Domínguez-Hernández R, Oyagüez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. J Viral Hepat. 2017 Mar 8. PMID: 28273410.
 
2: Hunt B, Mocarski M, Valentine WJ, Langer J. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA. Adv Ther. 2017 Mar 9. PMID: 28281218.
 
3: May AM, et al. Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study. BMJ Open. 2017 Mar 6;7(3):e012187. PMID: 28264824.
 
4: Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int. 2017 Mar 6. PMID: 28265718.
 
5: Schmier JK, Ong KL, Fonarow GC. Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System. Clin Cardiol. 2017 Mar 8.PMID: 28272808.
 
6: Ting EE, Sander B, Ungar WJ. Systematic review of the cost-effectiveness of influenza immunization programs. Vaccine. 2017 Mar 8. PMID:28284681.
 
7: Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar 8. PMID: 28271250.
 
8: Wirth D, Dass R, Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. BMC Health Serv Res. 2017 Mar 8;17(1):182. PMID: 28270207.
 
9: Woods B, et al. Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee. PLoS One. 2017 Mar 7;12(3):e0172749. PMID: 28267751.
 
10: Xu X, Yonkers KA, Ruger JP. Economic evaluation of a behavioral intervention versus brief advice for substance use treatment in pregnant women: results from a randomized controlled trial. BMC Pregnancy Childbirth. 2017 Mar 7;17(1):83. PMID: 28270105.
By CEA Registry Team on 3/13/2017 4:22 PM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Herd-protection effects in CEAs have significant effect in estimated ICERs: In a quantitative comparative analysis of the incremental-cost-effectiveness-ratios for childhood vaccinations with vs without vaccine herd-protection, inclusion of herd-protection effects had a substantial impact in the estimated ICERs. (19) 
  • Three breast cancer treatments have similar outcomes, but cost-effectiveness varies by perspective: For selected patients, accelerated partial breast irradiation techniques were found to have the same outcomes as whole breast irradiation. From a healthcare perspective, whole breast radiation was found to be the least costly option, but accelerated partial breast irradiation was the least costly from a patient perspective. (31)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published February 27- March 3, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
 
1: Aitken E, Thomson P, Bainbridge L, Kasthuri R, Mohr B, Kingsmore D. A randomized controlled trial and cost-effectiveness analysis of early cannulation arteriovenous grafts versus tunneled central venous catheters in patients requiring urgent vascular access for hemodialysis. J Vasc Surg. 2017 Mar;65(3):766-774. PMID: 28236919.
 
2: Bergmann JN, et al. Outcomes and Cost-Effectiveness of Integrating HIV and Nutrition
Service Delivery: Pilots in Malawi and Mozambique. AIDS Behav. 2017 Mar;21(3):703-711. PMID: 27094787.
 
3: Bonsang-Kitzis H, et al. Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. PLoS One. 2017 Feb 27;12(2): e0169962. PMID: 28241044.
 
4: Bozkaya D, Livingston T, Migliaccio-Walle K, Odom T. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2017 Mar;20(3):297-302. PMID: 27822961.
 
5: Carter MJ, Gilligan AM, Waycaster CR, Schaum K, Fife CE. Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers. J Med Econ. 2017 Mar;20(3):253-265. PMID: 27774840.
 
6: Chen LW, Wilson FA, Gregg A, Gupta N, Bekmuratova S, Palm D. Measuring the Cost and Value of Quality Improvement Initiatives for Local Health Departments. J Public Health Manag Pract. 2017 Mar 1.PMID: 28257401.
 
7: Chowers M, Shavit O. Economic evaluation of universal prenatal HIV screening compared with current 'at risk' policy in a very low prevalence country. Sex Transm Infect. 2017 Mar;93(2):112-117. PMID: 28213577.
 
8: Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLoS One. 2017 Mar 1;12(3):e0172731. PMID: 28248984.
 
9: Comans T, Mihala G, Sakzewski L, Boyd RN, Scuffham P. The cost-effectiveness of a web-based multimodal therapy for unilateral cerebral palsy: the Mitii randomized controlled trial. Dev Med Child Neurol. 2017 Mar 1. PMID: 28247406.
 
10: Coyle K, et al. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism. Thromb Res. 2017 Mar;151:67-71.PMID: 28160670.
 
11: Fritz JM, Kim M, Magel JS, Asche CV. Cost-Effectiveness of Primary Care Management With or Without Early Physical Therapy for Acute Low Back Pain: Economic Evaluation of a Randomized Clinical Trial. Spine (Phila Pa 1976). 2017 Mar;42(5):285-290. PMID: 27270641.
 
12: Gao LL, Basta M, Kanchwala SK, Serletti JM, Low DW, Wu LC. Cost-effectiveness of microsurgical reconstruction for head and neck defects after oncologic resection. Head Neck. 2017 Mar;39(3):541-547.PMID: 27898195.
 
13: Gold MR, Padhiar A, Mealing S, Sidhu MK, Tsintzos SI, Abraham WT. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. JACC Heart Fail. 2017 Mar;5(3):204-212. PMID: 28254126.
 
14: Gyftopoulos S, Subhas N. Measuring Value, Outcomes, and Cost-Effectiveness in MSK Radiology: A Primer. Semin Musculoskelet Radiol. 2017 Feb;21(1):1-2. PMID: 28253526.
 
15: Hatch MD, Daniels SD, Glerum KM, Higgins LD. The cost effectiveness of vancomycin for preventing infections after shoulder arthroplasty: a break-even analysis. J Shoulder Elbow Surg. 2017 Mar;26(3):472-477. PMID: 27727049.
 
16: Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. J Med Econ. 2017 Mar;20(3):228-238.  PMID: 27730845.
 
17: Hernández-Gago Y, Lombardero-Pin M, Ortega de la Cruz C, Maciuniak PA, Díez
Del Pino A. Cost effectiveness of a protocol using palivizumab in preterm infants. Farm Hosp. 2017 Mar 1;41(2):169-186. PMID: 28236796.
 
18: Hirsch JD, et al. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic. J Manag Care Spec Pharm. 2017 Mar;23(3):318-326. PMID: 28230459.
 
19: Holubar M, Stavroulakis MC, Maldonado Y, Ioannidis JP, Contopoulos-Ioannidis D. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis. PLoS One. 2017 Mar 1;12(3):e0172414. PMID: 28249046.
 
20: Hwang HJ, Guidi MA, Curvale C, Lasa J, Matano R. Post-ERCP pancreatitis: early precut or pancreatic duct stent? A multicenter, randomized-controlled trial and cost-effectiveness analysis. Rev Esp Enferm Dig. 2017 Mar;109(3):174-179.PMID: 28185468.
 
21: Ibekwe E, Haigh C, Duncan F, Fatoye F. Economic impact of Routine Opt-out Antenatal HIV Screening: A Systematic Review. J Clin Nurs. 2017 Mar 2. PMID: 28252818.
 
22: Jeong YJ, et al. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea. J Clin Pharm Ther. 2017 Mar 1. PMID: 28251662.
 
23: Johns B, Doroshenko O, Tarantino L, Cowley P. The Cost-Effectiveness of Integrating HIV Counseling and Testing into Primary Health Care in the Ukraine. AIDS Behav. 2017 Mar;21(3):655-664. PMID: 27654316.
 
24: Kameda M, Yamada S, Atsuchi M, Kimura T, Kazui H, Miyajima M, Mori E,Ishikawa M, Date I; SINPHONI and SINPHONI-2 Investigators.. Cost-effectiveness analysis of shunt surgery for idiopathic normal pressure hydrocephalus based on the SINPHONI and SINPHONI-2 trials. Acta Neurochir (Wien). 2017 Mar 1. PMID: 28251346.
 
25: Kim DJ, Kim HS, Oh M, Kim EY, Shin JG. Cost Effectiveness of Genotype-Guided
Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the
Fee-for-Service System. Appl Health Econ Health Policy. 2017 Feb 28. PMID: 28247199.
 
26: Laguna MP. Re: Cost-Effectiveness of Management Options for Small Renal Mass:
A Systematic Review. J Urol. 2017 Mar;197(3 Pt 1):602-603. PMID: 28208510.
 
27: Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clin Drug Investig. 2017 Mar;37(3):233-247. PMID:
27928739.
 
28: Liow MH, Agrawal K, Anderson DW, Freiberg AA, Rubash HE, Kwon YM. Unsuspected
Malignancies in Routine Femoral Head Histopathologic Examination During Primary Total Hip Arthroplasty: Cost-Effectiveness Analysis. J Arthroplasty. 2017 Mar;32(3):735-742. PMID: 27697361.
 
29: Liu CY, Chen HC. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. Clin Drug Investig. 2017 Mar;37(3):285-293. PMID: 27988835.
 
30: Martinez JM, Anene A, Bentley TG, Cangelosi MJ, Meckley LM, Ortendahl JD, Montero AJ. Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer. J Gastrointest Cancer. 2017 Mar;48(1):58-65.PMID: 28025817.
 
31: McGuffin M, Merino T, Keller B, Pignol JP. Who Should Bear the Cost of Convenience? A Cost-effectiveness Analysis Comparing External Beam and Brachytherapy Radiotherapy Techniques for Early Stage Breast Cancer. Clin Oncol (R Coll Radiol). 2017 Mar;29(3):e57-e63. PMID: 27956335.
 
32: Mock C. Strengthening the Methodologic Rigor of Cost-Effectiveness Studies in Global Surgery. World J Surg. 2017 Mar 2. PMID: 28255627.
 
33: Naunheim MR, Song PC, Franco RA, Alkire BC, Shrime MG. Surgical management of
bilateral vocal fold paralysis: A cost-effectiveness comparison of two treatments. Laryngoscope. 2017 Mar;127(3):691-697. PMID: 27578299.
 
34: Ophuis RH, Lokkerbol J, Heemskerk SC, van Balkom AJ, Hiligsmann M, Evers SM.
Cost-effectiveness of interventions for treating anxiety disorders: A systematic review. J Affect Disord. 2017 Mar 1;210:1-13. PMID: 27988373.
 
35: Padula WV, Millis MA, Worku AD, Pronovost PJ, Bridges JF, Meltzer DO. Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. J Med Econ. 2017 Mar;20(3):288-296. PMID: 27786569.
 
36: Pambrun T, et al. Contact-force guided single-catheter approach for pulmonary vein isolation: Feasibility, outcomes, and cost-effectiveness. Heart Rhythm. 2017 Mar;14(3):331-338. PMID: 27940124.
 
37: Pascacio-Villafán C, Birke A, Williams T, Aluja M. Modeling the cost-effectiveness of insect rearing on artificial diets: A test with a tephritid fly used in the sterile insect technique. PLoS One. 2017 Mar 3;12(3):e0173205. PMID: 28257496.
 
38: Prinja S, Kaur G, Malhotra P, Jyani G, Ramachandran R, Bahuguna P, Varma S. Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India. Indian J Hematol Blood Transfus. 2017 Mar;33(1):31-40. PMID: 28194053.
 
39: Qin G, Zhuang X. Cost-effectiveness of augmenting current perinatal hepatitis B prevention program with maternal antiviral therapy. Hepatology. 2017 Mar;65(3):1074-1075. PMID: 27785834.
 
40: Requena-Méndez A, et al. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis. Lancet Glob Health. 2017 Feb 27. PMID: 28256340.
 
41: Romero-Sanchiz P, et al. Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multi-center, three-armed randomized controlled trial conducted in primary care. PLoS One. 2017 Feb 27;12(2):e0172741. PMID: 28241025.
 
42: Samur S, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology. 2017 Mar;65(3):920-928. PMID: 27906472.
 
43: Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. J Comp Eff Res. 2017 Mar;6(2):97-108. PMID: 28118731.
 
44: Shanahan M, Hughes CE, McSweeney T, Griffin BA. Alternate policing strategies: Cost-effectiveness of cautioning for cannabis offences. Int J Drug Policy. 2017 Mar;41:140-147. PMID:28139329.
 
45: Smith GA. Erratum: Screening via CT angiogram after traumatic cervical spine fractures: narrowing imaging to improve cost effectiveness. Experience of a Level I trauma center. J Neurosurg Spine. 2017 Mar;26(3):404. PMID: 27911228.
 
46: Smith WB 2nd, Steinberg J, Scholtes S, Mcnamara IR. Medial compartment knee osteoarthritis: age-stratified cost-effectiveness of total knee arthroplasty, unicompartmental knee arthroplasty, and high tibial osteotomy. Knee Surg Sports Traumatol Arthrosc. 2017 Mar;25(3):924-933. PMID: 26520646.
 
47: Sun D, McCarthy TJ, Liberman DB. Cost-Effectiveness of Watchful Waiting in Acute Otitis Media. Pediatrics. 2017 Mar 3. PMID: 28258074.
 
48: Sun Y, You W, Almeida F, Estabrooks P, Davy B. The Effectiveness and Cost of Lifestyle Interventions Including Nutrition Education for Diabetes Prevention: A Systematic Review and Meta-Analysis. J Acad Nutr Diet. 2017 Mar;117(3):404-421.e36. PMID: 28236962.
 
49: Tufail A, et al. Automated Diabetic Retinopathy Image Assessment Software: Diagnostic
Accuracy and Cost-Effectiveness Compared with Human Graders. Ophthalmology. 2017 Mar;124(3):343-351. PMID: 28024825.
 
50: Visser JJ, Oei EH, Hunink MG. Using Cost-Effectiveness Analysis to Measure Value in Musculoskeletal Imaging. Semin Musculoskelet Radiol. 2017 Feb;21(1):37-42. PMID: 28253532.
 
51: Wali AR, Park CC, Brown JM, Mandeville R. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion. Neurosurg Focus. 2017 Mar;42(3):E11. PMID: 28245686.
 
52: Wei CY, Quek RG, Villa G, Gandra SR, Forbes CA, Ryder S, Armstrong N, Deshpande S, Duffy S, Kleijnen J, Lindgren P. A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. Pharmacoeconomics. 2017 Mar;35(3):297-318. PMID: 27785772.
 
53: Wojcik R, Lowin J, Vilardell D, Maeso S, Ruiz L, Lear JT, Morton C. The cost-effectiveness of 5-FU-SA in the treatment of actinic keratoses of the face and scalp in the UK secondary care setting. J Med Econ. 2017 Mar;20(3):221-227. PMID: 27715356
By CEA Registry Team on 2/28/2017 10:35 AM
 This week we highlighted findings from recently published cost-effectiveness studies:
  • Text message-based health intervention predicted to improve health and be cost-saving: Using text messages to send health-related advice, motivation, information, and support to patients with coronary heart disease is expected to promote better health outcomes and overall cost savings in the Australian health care system. (1)
  • Cost-effectiveness of a H. pylori serology-based screening program found to be favorable: In New Zealand, a nationwide screening for H. pylori was found to avert future gastric cancer cases over a lifetime at a favorable cost-effective threshold. (11).
  • Gap in evidence on the cost-effectiveness of genetic diagnostic testing for Autism Spectrum Disorder: An urgent need for economic evaluations on genetic test for Autism Spectrum Disorder was revealed after a systematic review found a lack of evidence available. (14)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published February 20-24, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Burn E, et al. Cost-effectiveness of a text message programme for the prevention of recurrent cardiovascular events. Heart. 2017 Feb 24. PMID: 28235776.
 
2: Chetty M, Kenworthy JJ, Langham S, Walker A, Dunlop WC. A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence. Addict Sci Clin Pract. 2017 Feb 24;12(1):6.PMID: 28235415.
 
3: Duarte A, Walker S, Littlewood E, Brabyn S, Hewitt C, Gilbody S, Palmer S. Cost-effectiveness of computerized cognitive-behavioural therapy for the treatment of depression in primary care: findings from the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. Psychol Med. 2017 Feb 23:1-11. PMID: 28228182.
 
4: Franken MD, et al. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. Eur J Cancer. 2017 Feb 23;75:204-212. PMID: 28237866.
 
5: Hassmiller Lich K, et al. Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer
Screening Interventions, North Carolina. Prev Chronic Dis. 2017 Feb 23;14:E18. PMID: 28231042.
 
6: Johnsen NV, Penson DF, Reynolds WS, Milam DF, Dmochowski RR, Kaufman MR. Cost-effective management of pelvic fracture urethral injuries. World J Urol. 2017 Feb 22. PMID:
28229209.
 
7: Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. J Clin Oncol. 2017 Feb 21:JCO2016696336. PMID: 28221865.
 
8: Larsen B, Marcus B, Pekmezi D, Hartman S, Gilmer T. A Web-Based Physical Activity Intervention for Spanish-Speaking Latinas: A Costs and Cost-Effectiveness Analysis. J Med Internet Res. 2017 Feb 22;19(2):e43. PMID: 28228368.
 
9: Lian JX, McGhee SM, So C, Chau J, Wong CK, Wong WC, Lam CL. Five-year cost-effectiveness of Patient Empowerment Programme (PEP) for type 2 diabetes mellitus in primary care. Diabetes Obes Metab. 2017 Feb 23. PMID: 28230312.
 
10: Mezquita-Raya P, et al. Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Ther. 2017 Feb 21. PMID: 28224463.
 
11: Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis. 2017 Feb 20;17(1):156. PMID: 28219322.
 
12: Venderink W, Govers TM, de Rooij M, Fütterer JJ, Sedelaar JP. Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion. AJR Am J Roentgenol. 2017 Feb 22:1-6. PMID: 28225639.
 
13: von Dach E, Morel CM, Murthy A, Pagani L, Macedo-Vinas M, Olearo F, Harbarth S. Comparing The Cost-Effectiveness Of Linezolid To Trimethoprim/Sulfamethoxazole Plus Rifampicin For The Treatment Of MRSA Infection: A Health-Care System Perspective. Clin Microbiol Infect. 2017 Feb 20. PMID: 28232163.
 
14: Ziegler A, Rudolph-Rothfeld W, Vonthein R. Genetic Testing for Autism Spectrum Disorder is Lacking Evidence of Cost-Effectiveness. A Systematic Review. Methods Inf Med. 2017 Feb 21. PMID: 28220926.
 
By CEA Registry Team on 2/21/2017 4:36 PM
By Josh Cohen, Jordan Anderson, and Peter Neumann
 
Our  new article in Value in Health examines three prominent value frameworks designed to help evaluate therapies: Memorial Sloan Kettering Cancer Center’s DrugAbacus, the American Society of Clinical Oncologists (ASCO) framework, and the Institute for Clinical and Economic Review (ICER) framework. Our paper develops a series of case studies that illustrate areas where the frameworks are not yet well aligned with certain notions of value, namely if value is proportional to a therapy’s benefit, if value reflects factors relevant to framework users, if weights reflect user preferences, and if value estimates used to inform therapy prices reflect per-person benefit. We conclude that although the value frameworks we reviewed capture value in a way that is important to various audiences, they are not always logical or consistent. 
 
To find out how you can learn more by participating in our research Center’s Value Frameworks Workshop, contact Julie Lannon (jlannon@tuftsmedicalcenter.org).
 
Reference
1: Cohen J, Anderson J, Neumann P. Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. Value in Health 2017;20:193-199.
By CEA Registry Team on 2/14/2017 9:53 AM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Framework for geographic targeting based on cost-effectiveness applied to priority setting in malaria control: An approach using targeted geographic data to estimate intervention costs and effects is recommended for implementing malaria interventions in order to maximize available resources and work towards elimination (9)
  • Review of cost-effectiveness models in breast cancer screening highlights structural and methodological approaches: A systematic review revealed that models used in cost-effectiveness analysis employed varying disease progression assumptions and imprecise utility estimates (17)
 See below for a full list of all cost-utility studies and selected reviews and editorials published February 6-10, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Achana F, Petrou S, Khan K, Gaye A, Modi N; Medicines for Neonates Investigators. A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations. Eur J Health Econ. 2017 Feb 9. PMID: 28180977.
 
2: Bearz A, Berretta M, Tirelli U. Clinical Effectiveness and Cost-Effectiveness  of Target Therapies for Adult Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review. Curr Cancer Drug Targets. 2017 Feb 6. PMID:28176647.
 
3: Bierbaum M, Schöffski O, Schliemann B, Kösters C. Cost-utility analysis of dynamic intraligamentary stabilization versus early reconstruction after rupture of the anterior cruciate ligament. Health Econ Rev. 2017 Dec;7(1):8. PMID: 28168633.
 
4: Brockbank J, Wolowacz S. Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review. Pharmacoeconomics. 2017 Feb 10. PMID: 28185212.
 
5: Cadier B, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology. 2017 Feb 8. PubMed PMID: 28176349.
 
6: Capri S, Porta C, Delea TE. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. Clin Ther. 2017 Feb 9. PMID: 28189363.
 
7: Coppola A, D'Ausilio A, Aiello A, Amoresano S, Toumi M, Mathew P, Tagliaferri A; Potter Study Group.. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia. 2017 Feb 8. PMID: 28181369.
 
8: Cowie MR, Simon M, Klein L, Thokala P. The cost-effectiveness of real-time pulmonary artery pressure monitoring in heart failure patients: a European perspective. Eur J Heart Fail. 2017 Feb 7. PMID: 28176424.
 
9: Drake TL, Lubell Y, Kyaw SS, Devine A, Kyaw MP, Day NP, Smithuis FM, White LJ. Geographic Resource Allocation Based on Cost Effectiveness: An Application to Malaria Policy. Appl Health Econ Health Policy. 2017 Feb 10.  PMID: 28185133.
 
10: Hunter SA, Morris C, Nelson K, Snyder BJ, Poulton TB. Digital Breast Tomosynthesis: Cost-Effectiveness of Using Private and Medicare Insurance in Community-Based Health Care Facilities. AJR Am J Roentgenol. 2017 Feb 8:1-5. PMID: 28177646.
 
11: Hwang HJ, Guidi MA, Curvale C, Lasa J, Matano R. Post-ERCP pancreatitis: early precut or pancreatic duct stent? A multicenter, randomized-controlled trial and cost-effectiveness analysis. Rev Esp Enferm Dig. 2017 Feb 10. PMID: 28185468.
 
12: Kim JF, Nwaru BI, McCleary N, Stoddart A, Sheikh A. Investigating the accuracy, risk impact, and cost-effectiveness of component-resolved diagnostic test for food allergy: a systematic review protocol. NPJ Prim Care Respir Med.2017 Dec;27(1):10. PMID: 28184046.
 
13: Lachance CC, Jurkowski MP, Dymarz AC, Robinovitch SN, Feldman F, Laing AC, Mackey DC. Compliant flooring to prevent fall-related injuries in older adults: A scoping review of biomechanical efficacy, clinical effectiveness, cost-effectiveness, and workplace safety. PLoS One. 2017 Feb 6;12(2):e0171652. PMID: 28166265.
 
14: Orenstein EW, et al. Cost-effectiveness of maternal influenza immunization in Bamako, Mali: A decision analysis. PLoS One. 2017 Feb 7;12(2):e0171499. PMID: 28170416.
 
15: Pepe A, et al. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective. Clin Drug Investig. 2017 Feb 10. PMID: 28185140.
 
16: Schechner V, Carmeli Y, Leshno M. A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation. PLoS One. 2017 Feb 10;12(2):e0171327. PMID: 28187144.
 
17: Schiller-Frühwirth IC, Jahn B, Arvandi M, Siebert U. Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review. Appl Health Econ Health Policy. 2017 Feb 10. PMID: 28185134.
 
18: Seki Y, et al. Erratum to: A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study. BMC Res Notes. 2017 Feb 6;10(1):86. PMID: 28166808.
 
19: Shah L, Rojas M, Mori O, Zamudio C, Kaufman JS, Otero L, Gotuzzo E, Seas C, Brewer TF. Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru. Epidemiol Infect. 2017 Feb 6:1-11. PMID: 28162099.
 
20: Ten Haaf K, et al. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Med. 2017 Feb 7;14(2):e1002225. PMID: 28170394.
 
21: Xu S, Immaneni S, Hazen GB, Silverberg JI, Paller AS, Lio PA. Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis. JAMA Pediatr. 2017 Feb 6;171(2):e163909. PMID: 27918774.
 
22: Yue WW, Wang SR, Lu F, Li XL, Xu HX, Sun LP, Guo LH, He YP, Wang D, Yin ZQ. Corrigendum: Quality of Life and Cost-Effectiveness of Radiofrequency Ablation versus Open Surgery for Benign Thyroid Nodules: a retrospective cohort study. Sci Rep. 2017 Feb 10;7:41342. PMID: 28186108.
 
By CEA Registry Team on 2/6/2017 4:57 PM

This week we highlighted findings from recently published cost-effectiveness studies:

  • New insights into methodological derivation of thresholds used in global health: New paper reviews the underlying concepts of CEA thresholds, the derivation of the one and three times GDP per capital multipliers, and suggestions for improvement in global health research (46)
  • Use of specialized oral nutritional supplements suggests considerable cost-effectiveness: Providing specialized oral nutritional supplements to prevent and combat malnutrition in older hospitalized patients was found to extend the life of patients with favorable cost-effectiveness (58)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published January 30 – February 3, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Aichmair A, et al. Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS). Eur Spine J. 2017 Feb;26(2):501-509. PMID: 28040872.
 
2: Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. JACC Heart Fail. 2017 Feb;5(2):110-119. PMID: 28017351.
 
3: Barbosa C, Cowell A, Dowd W, Landwehr J, Aldridge A, Bray J. The cost-effectiveness of brief intervention versus brief treatment of Screening, Brief Intervention and Referral to Treatment (SBIRT) in the United States. Addiction. 2017 Feb;112 Suppl 2:73-81. PMID:28074567.
 
4: Bardach AE, et al. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health. 2017 Feb 2;17(1):152. PMID: 28148228.
 
5: Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, Yang Y, Li Q. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol. 2017 Feb;143(2):361-368. PMID: 27798730.
 
6: Choi SE, Seligman H, Basu S. Cost Effectiveness of Subsidizing Fruit and Vegetable Purchases Through the Supplemental Nutrition Assistance Program. Am J Prev Med. 2017 Jan 30. PMID: 28153648.
 
7: Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom. Pharmacoeconomics. 2017 Feb;35(2):237-248. PMID: 27787744.
 
8: Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thromb Res. 2017 Feb;150:53-58. PMID: 28039844.
 
9: Costa D, Peixoto Lima R. Cost-effectiveness of ambulatory blood pressure monitoring in the management of hypertension. Rev Port Cardiol. 2017 Jan 31. English, Portuguese. PMID: 28159431.
 
10: Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thromb Res. 2017 Feb;150:121-122. PMID: 28007401.
 
11: Cradock AL, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Prev Med. 2017 Feb;95S:S17-S27. PMID: 27773710.
 
12: Critchlow S, Hirst M, Akehurst R, Phillips C, Philips Z, Sullivan W, Dunlop WC. A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. J Med Econ. 2017 Feb;20(2):129-139. PMID: 27563752.
 
13: Cubo E, et al. Prospective study on cost-effectiveness of home-based motor assessment in Parkinson's disease. J Telemed Telecare. 2017 Feb;23(2):328-338. PMID: 27000142.
 
14: de Vos AS, Janssen MP, Zaaijer HL, Hogema BM. Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands. Transfusion. 2017 Jan 31. PMID: 28144956.
 
15: Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther. 2017 Feb;45(3):455-467. PMID: 27910116.
 
16: Elmallah RK, Chughtai M, Khlopas A, Bhowmik-Stoker M, Bozic KJ, Kurtz SM, Mont MA. Determining Cost-Effectiveness of Total Hip and Knee Arthroplasty Using  the Short Form-6D Utility Measure. J Arthroplasty. 2017 Feb;32(2):351-354. PMID: 27665243.
 
17: Floodeen H, Hallböök O, Hagberg LA, Matthiessen P. Costs and resource use following defunctioning stoma in low anterior resection for cancer - A long-term analysis of a randomized multicenter trial. Eur J Surg Oncol. 2017 Feb;43(2):330-336. PMID: 28069399.
 
18: Fust K, et al. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):39-52. PMID: 28064553.
 
19: Gilden DM, et al. Treatment patterns and cost-effectiveness of first line treatment of
advanced non-squamous non-small cell lung cancer in Medicare patients. J Med Econ. 2017 Feb;20(2):151-161. PMID: 27574722.
 
20: Grabner M, Winegar DA, Punekar RS, Quimbo RA, Cziraky MJ, Cromwell WC. Cost
Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. Am J Cardiol. 2017 Feb 1;119(3):404-409. PMID: 27887691.
 
21: Groessl EJ, Sklar M, Laurent DD, Lorig K, Ganiats TG, Ho SB. Cost-Effectiveness of the Hepatitis C Self-Management Program. Health Educ Behav. 2017 Feb;44(1):113-122. PubMed PMID: 27206463.
 
22: Hagberg L, Hermansson L, Fredriksson C, Pettersson I. Cost-effectiveness of powered mobility devices for elderly people with disability. Disabil Rehabil Assist Technol. 2017 Feb;12(2):115-120. PMID: 25634493.
 
23: Hernandez I, Smith KJ, Zhang Y. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res. 2017 Feb;150:123-130. PMID: 27771008.
 
24: Hojjat H, et al. Cost-effectiveness of routine computed tomography in the evaluation
of idiopathic unilateral vocal fold paralysis. Laryngoscope. 2017 Feb;127(2):440-444. PMID: 27601300.
 
25: Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, Velcheti V. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. J Med Econ. 2017 Feb;20(2):140-150. PMID: 27571538.
 
26: Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol. 2017 Feb;52(2):238-241. PMID: 27806639.
 
27: Kearns B, Chilcott J, Whyte S, Preston L, Sadler S. Erratum to: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Med. 2017 Feb 3;15(1):31. PMID: 28158977.
 
28: Kievit W, Maurits JS, Arts EE, van Riel PL, Fransen J, Popa CD. Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):175-182. PMID: 27159060.
 
29: Landfeldt E, Alfredsson L, Straub V, Lochmüller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 Feb;35(2):249-258. PMID: 27798808.
 
30: Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):85-98. PMID: 27366939.
 
31: Lawson R, Ryan J, King F, Goh JW, Tichy E, Marsh K. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK. Pharmacoeconomics. 2017 Feb;35(2):225-235. PMID: 27663572.
 
32: Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. J Gen Intern Med. 2017 Feb;32(2):159-167. PMID: 27743284.
 
33: Leal J, et al. Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study. J Bone Miner Res. 2017 Feb;32(2):203-211.PMID: 27632945.
 
34: Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy. 2017 Feb;15(1):65-74. PMID: 27480538.
 
35: McLean TR. Interval Appendectomy: Cost-Effectiveness. J Am Coll Surg. 2017 Feb;224(2):219. PMID: 28129836.
 
36: Moradi-Lakeh M, Yaghoubi M, Hajebi A, Malakouti SK, Vasfi MG. Cost-effectiveness of aftercare services for people with severe mental disorders: an analysis parallel to a randomised controlled clinical trial in Iran. Health Soc Care Community. 2017 Feb 1. PMID: 28147433.
 
37: Mori T, Crandall CJ, Ganz DA. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. Osteoporos Int. 2017 Feb;28(2):585-595. PMID: 27726000.
 
38: Muralidhar V, Nguyen PL. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urol Oncol. 2017Feb;35(2):76-85. PMID:27473636.
 
39: Neidell M, Lamster IB, Shearer B. Cost-effectiveness of diabetes screening initiated through a dental visit. Community Dent Oral Epidemiol. 2017 Feb 1. PMID: 28145564.
 
40: Osterberg EC, Murphy G, Harris CR, Breyer BN. Cost-effective Strategies for the Management and Treatment of Urethral Stricture Disease. Urol Clin North Am. 2017 Feb;44(1):11-17. PMID:27908365.
 
41: Panman C, Wiegersma M, Kollen BJ, Berger MY, Lisman-Van Leeuwen Y, Vermeulen
KM, Dekker JH. Two-year effects and cost-effectiveness of pelvic floor muscle training in mild pelvic organ prolapse: a randomised controlled trial in primary care. BJOG. 2017 Feb;124(3):511-520. PMID: 26996291.
 
42: Pedersen K, Sørbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG. 2017 Feb;124(3):474-484. PMID: 27264207.
 
43: Permsuwan U, Dilokthornsakul P, Thavorn K, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. J Med Econ. 2017 Feb;20(2):171-181. PMID: 27645706.
 
44: Qu XM, Louie AV, Ashman J, Wasif N. Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):339-346. PMID: 28068242.
 
45: Ristau BT, Geynisman DM. Patient-reported and Cost-effectiveness Outcomes Are
Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2017 Feb;71(2):210-212. PMID: 27638095.
 
46: Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017 Feb;32(1):141-145. PMID: 27452949.
 
47: Shafie AA, Ng CH, Tan YP, Chaiyakunapruk N. Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. Pharmacoeconomics. 2017 Feb;35(2):141-162. PMID: 27752998.
 
48: Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin. 2017 Feb;33(2):359-369. PMID: 27817216.
 
49: Shireman TI, et al. Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for
Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). Stroke. 2017 Feb;48(2):379-387. PMID:28028150.
 
50: Smith SR, et al. Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):234-242. PMID: 27111538.
 
51: Swart E, Laratta J, Slobogean G, Mehta S. Operative Treatment of Rib Fractures in Flail Chest Injuries: A Meta-analysis and Cost-Effectiveness Analysis. J Orthop Trauma. 2017 Feb;31(2):64-70. PMID: 27984449.
 
52: Vidal J, Slof J, Serrano D, Marqués T, Kumru H, Benito-Penalva J. Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):67-76. PMID: 27142176.
 
53: Vodicka EL, et al. Costs of integrating cervical cancer screening at an HIV clinic in Kenya. Int J Gynaecol Obstet. 2017 Feb;136(2):220-228.
 
54: Wang J, Chmielowski B, Pellissier J, Xu R, Stevinson K, Liu FX. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States. J Manag Care Spec Pharm. 2017 Feb;23(2):184-194. PMID: 28125365.
 
55: Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD,Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. PMID: 27923549.
 
56: Yanagi Y, Fukuda A, Barzey V, Adachi K. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan. J Med Econ. 2017 Feb;20(2):204-212. PMID: 27701921.
 
57: Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int. 2017 Feb;28(2):643-652. PMID: 27743068.
 
58: Zhong Y, Cohen JT, Goates S, Luo M, Nelson J, Neumann PJ. The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. Appl Health Econ Health Policy. 2017 Feb;15(1):75-83. PMID: 27492419.
 
By CEA Registry Team on 2/3/2017 11:40 AM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Various colorectal cancer screening strategies compared on relative impact: Among thirteen different screening strategies for colorectal cancer, colonoscopy was determined to be the most cost-effective strategy (1)
  • Addition of bedaquiline to treatment regimen of multidrug-resistant tuberculosis found to be effective: Adding bedaquiline to the treatment regimen of multidrug-resistant tuberculosis in select high burden countries led to improvements in health outcomes and reductions in healthcare costs (9)
  • Initial plus extended treatment with apixaban for the treatment of venous thromboembolism found to be cost-effective: In the UK, initial plus extended treatment with apixaban for the treatment and prevention of venous thromboembolism was found to be a cost-effective alternative to low-molecular-weight heparin and vitamin K antagonist (8)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published January 23-27, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Barzi A, Lenz HJ, Quinn DI, Sadeghi S. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 Jan 24. PMID: 28117881.
 
2: Brar H, Hogen L, Covens A. Cost-effectiveness of sentinel node biopsy and pathological ultrastaging in patients with early-stage cervical cancer. Cancer. 2017 Jan 24. PMID: 28117888.
 
3: Favato G, Noikokyris E, Vecchiato R. Ecological validity of cost-effectiveness models of universal HPV vaccination: a protocol for a systematic review. Syst Rev. 2017 Jan 25;6(1):17. PMID: 28118846.
 
4: Goulding JM, Harper N, Kennedy L, Martin KR. Cost-effectiveness in Psychodermatology: A Case Series. Acta Derm Venereol. 2017 Jan 25. PMID: 28120000.
 
5: Guarda AS, Schreyer CC, Fischer LK, Hansen JL, Coughlin JW, Kaminsky MJ, Attia E, Redgrave GW. Intensive treatment for adults with anorexia nervosa: The cost of weight restoration. Int J Eat Disord. 2017 Jan 27. PMID: 28130794.
 
6: Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N. Evaluation of the long-term cost-effectiveness of liraglutide versus lixisenatide for treatment of type 2diabetes mellitus in the UK setting. Diabetes Obes Metab. 2017 Jan 26. PMID: 28124820.
 
7: Kearns B, Rafia R, Leaviss J, Preston L, Brazier JE, Palmer S, Ara R. The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Serv Res. 2017 Jan 24;17(1):78. PMID: 28118838.
 
8: Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, Cohen AT. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res. 2017 Jan 23;17(1):74. PMID: 28114939.
 
9: Lu X, Smare C, Kambili C, El Khoury AC, Wolfson LJ. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries. BMC Health Serv Res. 2017 Jan 26;17(1):87.PMID: 28122562.
 
10: Sartori AM, Rozman LM, Decimoni TC, Leandro R, Novaes HM, de Soárez PC. A systematic review of health economic evaluations of vaccines in Brazil. Hum Vaccin Immunother. 2017 Jan 27:0. PMID: 28129026.
 
11: Sawad AB, Seoane-Vazquez E, Rodriguez-Monguio R, Turkistani F. Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. J Comp Eff Res. 2017 Jan 25. PMID: 28118731.
 
12: Schilling C, Petrie D, Dowsey MM, Choong PF, Clarke P. The Impact of Regression to the Mean on Economic Evaluation in Quasi-Experimental Pre-Post Studies: The Example of Total Knee Replacement Using Data from the Osteoarthritis Initiative. Health Econ. 2017 Jan 27. PMID: 28127856.
 
13: Sharma M, Seoud M, Kim JJ. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon. Vaccine. 2017 Jan 23;35(4):564-569. PMID: 28017434.
 
14: Stark Z, Schofield D, Alam K, Wilson W, Mupfeki N, Macciocca I, Shrestha R, White SM, Gaff C. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017 Jan 26. PMID: 28125081.
 
15: Wang Y, Yan BP, Liew D, Lee VW. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Pharmacogenomics J. 2017 Jan 24. PubMed PMID: 28117433.
 
By CEA Registry Team on 2/2/2017 11:15 AM
 By Elle Pope
A new commentary published today explores the meaning and impact, as well as remaining questions surrounding the passage of the 21st Century Cures Act and corresponding FDA draft guidance on communications of healthcare economic information.

 

By CEA Registry Team on 1/24/2017 3:44 PM
By Paige Lin, Ph.D.

Would you test your newborn for a rare but serious genetic disorder for which no direct treatment is available?
 
In a paper published this week in Pediatric Neurology, my colleagues and I demonstrate that most people would prefer testing their newborn for Spinal Muscular Atrophy (SMA) and express a reasonably high willingness to pay for the test, even in the absence of direct treatment [1].
 
SMA, the most fatal genetic neuromuscular disease among children, affects approximately 1 in 10,000 infants [2]. While early diagnosis can provide a window of opportunity for early intervention, current mandatory newborn screening programs in the United States do not require SMA testing primarily due to lacking disease-modifying therapy, until very recently [3].
 
In order to gauge the public’s preferences for SMA testing for newborns, we surveyed 982 US adults and asked how much, if any, they would pay out-of-pocket for the test using a bidding game approach. Each respondent was presented with two scenarios: the standard of care (no available treatment) and one of three hypothetical substitute scenarios that were randomly assigned:
 
  1. Improved functioning: New treatment improves functioning, but does not affect survival
  2. Improved survival: New treatment may improve survival, but it does not improve functioning
  3. Improved functioning and survival: New treatment would improve both functioning and survival
 
From this survey, we found that most people (79%) would prefer to test their newborn for SMA even without a treatment available.  A greater proportion (85% to 86%) would prefer the test if a treatment improved either functioning or survival, respectively. The vast majority (87%) would opt to pay for the test if an available treatment improved both functioning and survival. Respondents also demonstrated an equitably high willingness-to-pay value for the test (average $253 to $297).
 
Despite preferences for the test information, adding SMA to national newborn screening programs remains controversial because currently there is insufficient evidence on long-term patient outcomes as a result of early identification and early treatment for SMA at a population level. Our results provide insight into how the general public views the value of SMA testing, and how potential treatment benefits may affect their testing decisions.  Our findings add a new dimension to the discussions parents, physicians, and policymakers should have on whether SMA screening should be legislatively mandated.    
 
Tufts Medical Center received research funding support for this study from Biogen, which markets the first FDA-approved SMA treatment SPINRAZA™ (nusinersen).
 
[1] Lin PJ, Yeh WS, Neumann PJ. Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy. Pediatr Neurol. 2017 Jan;66:69-75. doi: 10.1016/j.pediatrneurol.2016.09.008. PubMed PMID: 27769729.
[2] Dolgin E. Call in the backup. Nat Med. 2012; 18:1602-1606.
[3] U.S. Food & Drug Administration. FDA approves first drug for spinal muscular atrophy [Press release]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm534611.htm
By CEA Registry Team on 1/23/2017 12:42 PM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Expert panel released updated guidelines for cost-effectiveness analysis: As U.S. health care system increases its use of cost-effectiveness analysis, a panel puts forth new recommendations (10)
  • New study evaluates costs to implement health behavior programs in early education: Administration and support services accounted for the largest amount of implementation costs for a healthy eating and physical activity program in children in Canada (16)
  • Highlights of common difficulties and how to avoid them in global surgery cost-effectiveness analysis: A new checklist has been devised to help low and middle income countries avoid common errors in global surgery cost-effectiveness analyses (17)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published January 16-20, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, Guery B, Dervaux B. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PLoS One. 2017 Jan 19;12(1):e0170258. PMID: 28103289.
 
2: Cockayne S, et al; REFORM study. Cohort Randomised Controlled Trial of a Multifaceted Podiatry Intervention for the Prevention of Falls in Older People (The REFORM Trial). PLoS One. 2017 Jan 20;12(1):e0168712. PMID: 28107372.
 
3: Drake TL, Lubell Y. Malaria and Economic Evaluation Methods: Challenges and Opportunities. Appl Health Econ Health Policy. 2017 Jan 19. PMID: 28105555.
 
4: Fust K, Parthan A, Maschio M, Gu Q, Li X, Lyman GH, Tzivelekis S, Villa G, Weinstein MC. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Rev Pharmacoecon Outcomes Res. 2017 Jan 20:1-14. PMID: 28064553.
 
5: Haines T, Bowles KA. Cost-effectiveness of using a motion-sensor biofeedback treatment approach for the management of sub-acute or chronic low back pain: economic evaluation alongside a randomised trial. BMC Musculoskelet Disord. 2017 Jan 17;18(1):18. PMID: 28095832.
 
6: Hill A, Redd C, Gotham D, Erbacher I, Meldrum J, Harada R. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ Open. 2017 Jan 20;7(1):e011965. PMID: 28110283.
 
7: Idrisov B, Murphy SM, Morrill T, Saadoun M, Lunze K, Shepard D. Implementation of methadone therapy for opioid use disorder in Russia - a modeled cost-effectiveness analysis. Subst Abuse Treat Prev Policy. 2017 Jan 20;12(1):4. PMID: 28107824.
 
8: Landstedt-Hallin L, Gundgaard J, Ericsson Å, Ellfors-Zetterlund S. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data. Curr Med Res Opin. 2017 Jan 20:1-9. PMID: 28035840.
 
9: Mustacchi G, Generali D. Cost-effectiveness and sustainability of breast cancer screening and new anticancer drugs. J Med Econ. 2017 Jan 20:1-7. PMID: 28105869.
 
10: Neumann PJ, Sanders GD. Cost-Effectiveness Analysis 2.0. N Engl J Med. 2017 Jan 19;376(3):203-205. PMID: 28099837.
 
11: Peabody JW, Quimbo S, Florentino J, Shimkhada R, Javier X, Paculdo D, Jamison D, Solon O. Comparative effectiveness of two disparate policies on child health: experimental evidence from the Philippines. Health Policy Plan. 2017 Jan 20. PMID: 28110265.
 
12: PLOS ONE Staff.. Correction: Cost-Effectiveness Analysis of Test-Based versus Presumptive Treatment of Uncomplicated Malaria in Children under Five Years in an Area of High Transmission in Central Ghana. PLoS One. 2017 Jan 20;12(1):e0170848. PMID: 28107534.
 
13: Qu XM, Mishra MV, Bauman GS, Slotman B, Mehta M, Gondi V, Louie AV. Cost-effectiveness of prophylactic cranial irradiation with hippocampal avoidance in limited stage small cell lung cancer. Radiother Oncol. 2017 Jan 18. PMID: 28109544.
 
14: Rivera F, Valladares M, Gea S, López-Martínez N. Cost-effectiveness analysis in the Spanish setting of the peak trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. J Med Econ. 2017 Jan 20:1-27. PMID: 28107090.
 
15: Rognoni C, Tarricone R. Healthcare resource consumption for intermittent urinary catheterisation: cost-effectiveness of hydrophilic catheters and budget impact analyses. BMJ Open. 2017 Jan 17;7(1):e012360. PMID: 28096251.
 
16: Sari N, Muhajarine N, Froehlich Chow A. The Saskatchewan/New Brunswick Healthy Start-Départ Santé intervention: implementation cost estimates of a physical activity and healthy eating intervention in early learning centers. BMC Health Serv Res. 2017 Jan 19;17(1):57. PMID: 28103861.
 
17: Shrime MG, Alkire BC, Grimes C, Chao TE, Poenaru D, Verguet S. Cost-Effectiveness in Global Surgery: Pearls, Pitfalls, and a Checklist. World J Surg. 2017 Jan 19. PMID: 28105528.
 
18: Simms KT, Hall M, Smith MA, Lew JB, Hughes S, Yuill S, Hammond I, Saville M, Canfell K. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. PLoS One. 2017 Jan 17;12(1):e0163509. PMID: 28095411.
 
19: Sundaram N, Chen C, Yoong J, Luvsan ME, Fox K, Sarankhuu A, La Vincente S, Jit M. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Vaccine. 2017 Jan 18. pii: S0264-410X(17)30010-5. PMID: 28109706.
 
20: Toth PP, Danese M, Villa G, Qian Y, Beaubrun A, Lira A, Jansen JP. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017 Jan 18:1-29. PMID: 28097904.
 
21: van der Laan DM, Elders PJ, Boons CC, Bosmans JE, Nijpels G, Hugtenburg JG. The (cost) effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomized controlled trial. Trials. 2017 Jan 19;18(1):29. PMID: 28103948.
 
22: Williams AN, Konopken YP, Keller CS, Castro FG, Arcoleo K, Barraza E, Patrick DL, Olson ML, Shaibi GQ. Culturally-grounded diabetes prevention program for obese Latino youth: Rationale, design, and methods. Contemp Clin Trials. 2017 Jan 16. PMID: 28104469.
 
23: Wilson RJ, Sulieman LM, VanHouten JP, Halpern JL, Schwartz HS, Devin CJ, Holt GE. Cost-utility of osteoarticular allograft versus endoprosthetic reconstruction for primary bone sarcoma of the knee: A markov analysis. J Surg Oncol. 2017 Jan 20. PMID: 28105636.
 
24: Zhao XW, Ma JX, Ma XL, Li F, He WW, Jiang X, Wang Y, Han B, Lu B. Interspinous process devices(IPD) alone versus decompression surgery for lumbar spinal stenosis(LSS): A systematic review and meta-analysis of randomized controlled trials. Int J Surg. 2017 Jan 18. pii: S1743-9191(17)30077-8. PMID: 28110031.
 
By CEA Registry Team on 1/18/2017 12:56 PM
This week we highlighted findings from recently published cost-effectiveness studies
  • PCSK9 inhibitors to reduce cardiovascular risk found to not add value to U.S. health system and is not profitable for private payers: The current price of PCSK9 inhibitors must be reduced by more than 70% in order to be considered a cost-effective drug to fight cardiovascular disease (1)
  • Diabetes risk-targeted prevention interventions likely cost-effective: A Type II diabetes prevention program targeted towards different at-risk groups in the UK was shown to be cost-effective,  particularly for certain high-risk groups (2)
  • Education program for preventing progression to Type II diabetes likely cost-effective: Compared to standard of care, the structured education program (Let's Prevent) demonstrated higher costs, but also had higher quality of life making it cost-effective at a threshold of £20 000/QALY in the UK (17)
  • Government policy to reduce dietary sodium intake estimated to be highly cost-effective worldwide: A regulation strategy coalescing industry contracts, government monitoring, and public education to reduce dietary sodium is thought to be highly cost effective worldwide (25)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published January 9-13, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Arrieta A, Page TF, Veledar E, Nasir K. Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives. PLoS One. 2017 Jan 12;12(1):e0169761. PMID: 28081164.
 
2: Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, Brunner E, Tabak A, Preston L, Chilcott J. The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabet Med. 2017 Jan 11. PMID: 28075544.
 
3: Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2017 Jan 10;35(2):166-174. PMID: 27870563.
 
4: Dilla T, Alexiou D, Chatzitheofilou I, Ayyub R, Lowin J, Norrbacka K. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m(2). J Med Econ. 2017 Jan 13:1-10. PMID: 28008768.
 
5: Ferket BS, Hunink MG, Khanji M, Agarwal I, Fleischmann KE, Petersen SE. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease. Heart. 2017 Jan 11. PMID: 28077465.
 
6: Ferrándiz L, et al. Internet-based skin cancer screening using clinical images alone or in conjunction with dermoscopic images: A randomized teledermoscopy trial. J Am Acad Dermatol. 2017 Jan 12. PMID: 28089728.
 
7: Fust K, Parthan A, Maschio M, Gu Q, Li X, Lyman GH, Tzivelekis S, Villa G, Weinstein MC. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Rev Pharmacoecon Outcomes Res. 2017 Jan 9. PMID: 28064553.
 
8: Gargano LM, Hajjeh R, Cookson ST. Pneumonia prevention: Cost-effectiveness analyses of two vaccines among refugee children aged under two years, Haemophilus influenzae type b-containing and pneumococcal conjugate vaccines, during a humanitarian emergency, Yida camp, South Sudan. Vaccine. 2017 Jan 11;35(3):435-442. PMID: 27989625.
 
9: Germar MJ, Purugganan C, Bernardino MS, Cuenca B, Chen YC, Li X, Van Kriekinge G, Lee IH. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule. Hum Vaccin Immunother. 2017 Jan 11:0. PMID: 28075249.
 
10: Gissel C, Götz G, Repp H. Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis. Z Rheumatol. 2017 Jan 13. PMID: 28084541.
 
11: Gonzalez L. A Focus on the Program of All-Inclusive Care for the Elderly (PACE). J Aging Soc Policy. 2017 Jan 13. PMID: 28085633.
 
12: Ivanidze J, et al. Effects of Radiation Exposure on the Cost-Effectiveness of CT Angiography and Perfusion Imaging in Aneurysmal Subarachnoid Hemorrhage. AJNR Am J Neuroradiol. 2017 Jan 12. PMID: 28082263.
 
13: Javanbakht M, et al. Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma: an economic evaluation based on data from the EAGLE trial. BMJ Open. 2017 Jan 13;7(1):e013254. PMID: 28087548.
 
14: Kearns BC, Thomas SM. Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study. BMJ Open. 2017 Jan 13;7(1):e013460. PMID:28087551.
 
15: Lahr MM, van der Zee DJ, Luijckx GJ, Vroomen PC, Buskens E. Centralising and optimising decentralised stroke care systems: a simulation study on short-term costs and effects. BMC Med Res Methodol. 2017 Jan 10;17(1):5. PMID: 28073360.
 
16: Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. Eur J Clin Microbiol Infect Dis. 2017 Jan 11. PMID: 28078557.
 
17: Leal J, Ahrabian D, Davies MJ, Gray LJ, Khunti K, Yates T, Gray AM. Cost-effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster-randomised controlled trial. BMJ Open. 2017 Jan 9;7(1):e013592. PMID: 28069625.

18: Lee JT, Lawson KD, Wan Y, Majeed A, Morris S, Soljak M, Millett C. Are cardiovascular disease risk assessment and management programmes cost effective? A systematic review of the evidence. Prev Med. 2017 Jan 10. PMID: 28087465.

19: Newhall K, Albright B, Tosteson A, Ozanne E, Trus T, Goodney PP. Cost-effectiveness of prophylactic appendectomy: a Markov model. Surg Endosc. 2017 Jan 11. PMID: 28078461.
 
20: Petracchi F, Paez C, Igarzabal L. Cost-effectiveness of cytogenetic evaluation of products of conception by chorionic villous sampling in recurrent miscarriage. Prenat Diagn. 2017 Jan 9. PMID: 28067420.
 
21: Rogers BL, Wilner LB, Maganga G, Walton SM, Suri DJ, Langlois BK, Chui KK, Boiteau JM, Vosti SA, Webb P. Program changes are effective and cost-effective in increasing the amount of oil used in preparing corn soy blend porridge for treatment of moderate acute malnutrition in Malawi. Matern Child Nutr. 2017 Jan 12. PMID: 28083927.
 
22: Sheng G, Chen S, Dong C, Zhang R, Miao M, Wu D, Tan SC, Liu C, Xiong T. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis. J Med Econ. 2017 Jan 12:1-11. PMID:27936995.
 
23: van Werkhoven CH, Postma DF, Mangen MJ, Oosterheert JJ, Bonten MJ; CAP-START study group.. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial. BMC Infect Dis. 2017 Jan 10;17(1):52. PMID: 28068956.
 
24: Walker KF, Dritsaki M, Bugg G, Macpherson M, McCormick C, Grace N, Wildsmith C, Bradshaw L, Smith GC, Thornton JG. Labour induction near term for women aged 35 or over: an economic evaluation. BJOG. 2017 Jan 11. PMID: 28075507.
 
25: Webb M, Fahimi S, Singh GM, Khatibzadeh S, Micha R, Powles J, Mozaffarian D. Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations. BMJ. 2017 Jan 10;356:i6699. PMID: 28073749.
 
26: Weber S, Pongratz G, Schneider M, Brinks R. Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis. Z Rheumatol. 2017 Jan 13. PMID: 28084542.
By CEA Registry Team on 1/9/2017 2:03 PM
This week we highlighted findings from recently published cost-effectiveness studies:
  • Canadian health system yields relatively good value for money: After applying separate adjustments to match total health spending, costs per QALY gained in Canada for the period from 1980-2012 were generally lower than those found for the US, but not for the UK (1)
  •  Alzheimer’s disease health-economic models face methodological and data challenges: A targeted review of the literature reveals a lack of current long-term large-scale data accurately representing the continuous, multifaceted, and heterogeneous disease process of Alzheimer’s.  These data gaps limit researchers’ ability to accurately estimate the cost-effectiveness of emerging treatments (10)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published January 2-6, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Ariste R, Di Matteo L. Value for money: an evaluation of health spending in Canada. Int J Health Econ Manag. 2017 Jan 3. PMID: 28050679.
 
2: Broekema AE, et al; FACET study group investigators. Study protocol for a randomised controlled multicentre study: the Foraminotomy ACDF Cost-Effectiveness Trial (FACET) in patients with cervical radiculopathy. BMJ Open. 2017 Jan 5;7(1):e012829. PMID: 28057652.
 
3: Buntrock C, Berking M, Smit F, Lehr D, Nobis S, Riper H, Cuijpers P, Ebert D. Preventing Depression in Adults With Subthreshold Depression: Health-Economic Evaluation Alongside a Pragmatic Randomized Controlled Trial of a Web-Based Intervention. J Med Internet Res. 2017 Jan 4;19(1):e5. PMID: 28052841.
 
4: Catalá-López F, Ridao M. Improving transparency of methods and results in cost-effectiveness analyses for cancer prevention, treatment and control. Med Clin (Barc). 2017 Jan 6;148(1):43-45. PMID: 27567331.
 
5: Christensen H, Trotter CL. Modelling the cost-effectiveness of catch-up 'MenB'
(Bexsero) vaccination in England. Vaccine. 2017 Jan 5;35(2):208-211. PMID: 27923519.
 
6: Dritsaki M, Achana F, Mason J, Petrou S. Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review. Pharmacoeconomics. 2017 Jan 6. PMID: 28063084.
 
7: Ericsson Å, Lundqvist A. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden. Appl Health Econ Health Policy. 2017 Jan 6. PMID: 28063135.
 
8: Galactionova K, Tediosi F, Camponovo F, Smith TA, Gething PW, Penny MA. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa. Vaccine. 2017 Jan 3;35(1):53-60. PMID: 27890400.
 
9: Groen H, Neelis EG, Poley MJ, Olieman JF, Scheenstra R, Krabbe PF, Dijkstra G, Rings EH. Intestinal rehabilitation for children with intestinal failure is cost-effective: a simulation study. Am J Clin Nutr. 2017 Jan 4. PubMed PMID: 28052886.
 
10: Gustavsson A, et al. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease. Alzheimers Dement. 2017 Jan 4. PubMed PMID: 28063281.
 
11: Hunt B, Ye Q, Valentine WJ, Ashley D. Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom. Diabetes Ther. 2017 Jan 5. PMID: 28058656.
 
12: Jacob V, et al; Community Preventive Services Task Force.. Cost and economic benefit of clinical decision support systems for cardiovascular disease prevention: a community guide systematic review. J Am Med Inform Assoc. 2017 Jan 3. pii: ocw160. PMID: 28049635.
 
13: Jan S, Wiseman V. Updated Recommendations for Cost-effectiveness Studies. JAMA. 2017 Jan 3;317(1):89-90. PMID: 28030693.
 
14: Jeemon P, et al. A PROgramme of Lifestyle Intervention in Families for Cardiovascular risk reduction (PROLIFIC Study): design and rationale of a family based randomized controlled trial in individuals with family history of premature coronary heart disease. BMC Public Health. 2017 Jan 5;17(1):10. PMID: 28056897.
 
15: Kim DY, Han KH, Jun B, Kim TH, Park S, Ward T, Webster S, McEwan P. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. PLoS One. 2017 Jan 6;12(1):e0167770. PMID: 28060834.
 
16: Kim ES, Kim JA, Lee EK. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea. Expert Rev Pharmacoecon Outcomes Res. 2017 Jan 3:1-9. PMID: 28010146.
 
17: Kripke K, et al. Correction: Modeling Impact and Cost-Effectiveness of Increased Efforts to Attract Voluntary Medical Male Circumcision Clients Ages 20-29 in Zimbabwe. PLoS One. 2017 Jan 3;12(1):e0169696. PMID: 28046126.
 
18: Kwon SH, Park SK, Byun JH, Lee EK. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea. Expert Rev Pharmacoecon Outcomes Res. 2017 Jan 3:1-9 PMID: 28019130.
 
19: Longcroft-Wheaton G, Bhandari P. Management of early colonic neoplasia: where are we now and where are we heading? Expert Rev Gastroenterol Hepatol. 2017 Jan 4. PMID: 28052695.
 
20: Maw AM, Shen NT, Fletcher DR. Updated Recommendations for Cost-effectiveness Studies. JAMA. 2017 Jan 3;317(1):89. PMID:28030694.
 
21: Nurmatov U, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy. 2017 Jan 6. PMID: 28058751.
 
22: Pollom EL, et al. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Radiology. 2017 Jan 3:161509. PMID: 28045603.
 
23: Reyes JF, et al. Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. Vaccine. 2017 Jan 5;35(2):345-352. PubMed PMID: 27916411.
 
24: Rojas A, Ganesh T, Walker A, Dingledine R. Ethylatropine Bromide as a Peripherally Restricted Muscarinic Antagonist. ACS Chem Neurosci. 2017 Jan 6. PubMed PMID: 28044440.
 
25: Sanders GD, Neumann PJ, Russell LB. Updated Recommendations for Cost-effectiveness Studies-Reply. JAMA. 2017 Jan 3;317(1):90. PMID: 28030697.
 
26: Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS One. 2017 Jan 3;12(1):e0169401. PMID: 28046099.
 
27: Steinke S, et alCost-effectiveness of an 8% Capsaicin Patch in the Treatment of Brachioradial Pruritus and Notalgia Paraesthetica, Two Forms of Neuropathic Pruritus. Acta Derm Venereol. 2017 Jan 4;96(7):71-76. PMID: 27241458.
 
28: Wilkinson D, Savulescu J. Cost-equivalence and Pluralism in Publicly-funded Health-care Systems. Health Care Anal. 2017 Jan 6. PubMed PMID: 28062971.
 
29: Yang MC, Chen YP, Tan EC, Leteneux C, Chang E, Chu CH, Lai CC. Epidemiology,
treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study. Jpn J Ophthalmol. 2017 Jan 6. doi: 10.1007/s10384-016-0496-3. PMID: 28062929.
 
30: Zhou Y, et al. Enrichment of total steroidal saponins from the extracts of Trillium  tschonoskii Maxim by macroporous resin and the simultaneous determination of eight steroidal saponins in final the product by HPLC. J Sep Sci. 2017 Jan 3. PubMed PMID: 28044421.
 
31: Zylla D, et al. Establishment of Personalized Pain Goals in Oncology Patients to Improve Care and Decrease Costs. J Oncol Pract. 2017 Jan 3:JOP2016017616. PMID: 28045611.
By CEA Registry Team on 1/4/2017 5:26 PM
Elle Pope, MPH and Peter J Neumann, ScD
 
A newly published article in Health Research Policy and Systems reveals several impediments in using cost-effectiveness evidence to inform policy setting in low- and middle-income countries (LMICs) [1]. Staff members from the Health Intervention and Technology Assessment Program (HITAP) surveyed key health policy experts in Vietnam, India and Bangladesh on barriers to the use of cost-effectiveness data to better inform the development of the Tufts Medical Center Global Health Cost-Effectiveness Analysis (GHCEA) Registry. This new database contains studies reporting cost-per-disability adjusted life year (DALY) averted information published in English language peer-reviewed journals [1].
 
Thirty-two participants from Health Ministries, universities, and non-governmental organizations were interviewed in-depth on existing barriers to using cost-effectiveness evidence to inform policy. The results revealed that, in the chosen settings of Bangladesh, India and Vietnam, the use of cost-effectiveness information is lacking due to limited knowledge among policymakers, inadequate human resources, and a lack of communication with health authorities in government sectors. All participants agreed that a cost-per-DALY registry would be useful for LMICs in expanding their access to otherwise limited economic data. Consensus on how the registry should be built included the following:
 
  1. Information broken down by diseases or cohorts to easily address specific policy questions
  2. Inclusion of both cost-per-DALY and cost-per-quality adjusted life year (QALY) information to encompass all available data
  3. Endorsements from reputable global health authorities to establish legitimacy
  4. Provision of basic information on research methods so that transferability of an intervention across different settings can be undertaken
As a greater number of LMICs move towards universal health coverage plans, the demand for economic evidence to inform coverage decisions will increase. The development of the cost-per-DALY database will aid technical advisors and health economic researchers in implementing appropriate health interventions in low-resources settings.
 
Reference
[1] Neumann PJ, Thorat T, Zhong Y, Anderson J, Farquhar M, Salem M, et al. (2016) A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS ONE 11(12) 2016.
By CEA Registry Team on 1/4/2017 2:34 PM
 This week we highlighted findings from recently published cost-effectiveness studies:
  • HPV vaccination of men who have sex with men has promising cost-effective results: A substantial decline in HPV-disease burden among men who have sex with men (MSM) was projected to occur after offering HPV vaccination in England, with cost-effective results likely even among HIV-positive MSM (12).
  • Development of the Global Health Cost-Effectiveness Analysis (GHCEA) Registry highlights strengths and limitations of literature: Despite the growing abundance of cost-per-DALY averted studies, adherence to good practices for conducting and reporting vary greatly (17). Read more here.
  • The use of hepatitis C virus (HCV) treatment is likely to be cost-effective for HCV infected cirrhotic patients in Italy:  The cost-effectiveness of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks was found to be mostly cost-effective for the treatment of genotype 3 HCV infected cirrhotic patients(18).
 
See below for a full list of all cost-utility studies and selected reviews and editorials published December 19-30, 2016.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y, Yun S, Abraham I, Erstad B. Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. Blood. 2016 Dec 29;128(26):3043-3051. PMID: 27793877.
 
2: Berm EJ, Gout-Zwart JJ, Luttjeboer J, Wilffert B, Postma MJ. A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy. PLoS One. 2016 Dec 29;11(12):e0169065. PMID: 28033366.
 
3: de Graaff B, Neil A, Si L, Yee KC, Sanderson K, Gurrin L, Palmer AJ. Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia. Appl Health Econ Health Policy. 2016 Dec 29. PMID: 28035629.
 
4: De Wals P, Zhou Z. Cost-Effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada. Pediatr Infect Dis J. 2016 Dec 23. PMID: 28027288.
 
5: Dilla T, Alexiou D, Chatzitheofilou I, Ayyub R, Lowin J, Norrbacka K. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2  diabetes mellitus in Spain in patients with BMI≥30 kg/m(2). J Med Econ. 2016 Dec 23:1-26. PMID: 28008768.
 
6: Dobbs RW, Magnan BP, Abhyankar N, Hemal AK, Challacombe B, Hu J, Dasgupta P, Porpiglia F, Crivellaro S. Cost effectiveness and robot-assisted urologic surgery: does it make dollars and sense? Minerva Urol Nefrol. 2016 Dec 22. PMID: 28008756.
 
7: Feldhaus I, LeFevre AE, Rai C, Bhattarai J, Russo D, Rawlins B, Chaudhary P, Thapa K. Optimizing treatment for the prevention of pre-eclampsia/eclampsia in Nepal: is calcium supplementation during pregnancy cost-effective? Cost Eff Resour Alloc. 2016 Dec 28;14:13. PMID:28035193.
 
8: Gharaibeh M, McBride A, Bootman JL, Patel H, Abraham I. Economic evaluation
for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer. J Med Econ. 2016 Dec 21:1-8. PMID: 27919186.
 
9: Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2016 Dec 27. PMID: 28026911.
 
10: Landstedt-Hallin L, Gundgaard J, Ericsson Å, Ellfors-Zetterlund S. Cost-effectiveness of switching to insulin degludec from other basal insulins: Evidence from Swedish real-world data. Curr Med Res Opin. 2016 Dec 30:1-29. PMID: 28035840.
 
11: Li J, Wen Z, Cai A, Tian F, Zhang L, Luo Y, Deng L, He J, Yang Y, Chen W. Real-world cost-effectiveness of infliximab for moderate-to-severe rheumatoid arthritis in a medium-sized city of China. J Comp Eff Res. 2016 Dec 20. PMID: 27997219.
 
12: Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, Choi YH, Tanton C, Soldan K, Jit M. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis. 2016 Dec 23. PMID: 28011615.
 
13: Lu S, Ye M, Ding L, Tan F, Fu J, Wu B. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget. 2016 Dec 27. PMID: 28036283.
 
14: Martinez JM, Anene A, Bentley TG, Cangelosi MJ, Meckley LM, Ortendahl JD, Montero AJ. Cost Effectiveness of Metal Stents in Relieving Obstructive Jaundice in Patients with Pancreatic Cancer. J Gastrointest Cancer. 2016 Dec 27. PMID: 28025817.
 
15: Mohiuddin S, Reeves B, Pufulete M, Maishman R, Dayer M, Macleod J, McDonagh T, Purdy S, Rogers C, Hollingworth W. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ Open. 2016 Dec 28;6(12):e014010. PMID:28031211.
 
16: Mohr NM, Stoltze A, Ahmed A, Kiscaden E, Shane D. Using continuous quantitative capnography for emergency department procedural sedation: a systematic review and cost-effectiveness analysis. Intern Emerg Med. 2016 Dec 28.PMID: 28032265.
 
17: Neumann PJ, Thorat T, Zhong Y, Anderson J, Farquhar M, Salem M, Sandberg E, Saret CJ, Wilkinson C, Cohen JT. A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS One. 2016 Dec 22;11(12):e0168512. PMID: 28005986.
 
18: Restelli U, Alberti A, Lazzarin A, Bonfanti M, Nappi C, Croce D. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. Eur J Health Econ. 2016 Dec 22. PMID: 28008546.
 
19: Sharma M, Seoud M, Kim JJ. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon. Vaccine. 2016 Dec 22. PMID: 28017434.
 
20: Shireman TI, et al. Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). Stroke. 2016 Dec 27. PMID: 28028150.
 
21: Smith KJ, Zimmerman RK, Nowalk MP, Lin CJ. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. J Am Geriatr Soc. 2016 Dec 26. PMID: 28024090.
 
22: Tufail A, et al. Automated Diabetic Retinopathy Image Assessment Software: Diagnostic
Accuracy and Cost-Effectiveness Compared with Human Graders. Ophthalmology. 2016
Dec 23. PMID: 28024825.
 
23: van de Graaf VA, et al. Cost-effectiveness of Early Surgery versus Conservative Treatment with Optional Delayed Meniscectomy for Patients over 45 years with non-obstructive meniscal tears (ESCAPE study): protocol of a randomised controlled trial. BMJ Open. 2016 Dec 21;6(12):e014381. PMID: 28003302.
 
24: Veenstra DL, Guzauskas GF, Villa KF, Boudreau DM. The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant. J Med Econ. 2016 Dec 23:1-27. PMID: 28008770.
 
25: White MT, Yeung S, Patouillard E, Cibulskis R. Costs and Cost-Effectiveness of Plasmodium vivax Control. Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):52-61.PMID: 28025283.
 
26: Wong C, Jiang M, You JH. Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Micro-needle Patch for Vaccine Delivery in Children. PLoS One. 2016 Dec 22;11(12):e0169030. PMID: 28006012.
 
27: Yan X, Gu X, Xu Z, Lin H, Wu B. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China. Adv Ther. 2016 Dec 20. PMID: 28000167.
By CEA Registry Team on 12/23/2016 10:28 AM

Peter J. Neumann Sc.D., and Teja Thorat, MPH.

In our just published paper in PLOS ONE, we introduce a new online database of cost-per-DALY averted studies, and also review the studies included and trends in publication [1].

The Global Health Cost-Effectiveness Analysis (GHCEA) Registry contains cost-per-DALY averted studies published in English language peer-reviewed journals. The GHCEA Registry currently includes 479 studies from 2000 through 2015. In our new study, we highlight the data collection process for the Registry. The data is accessible to the public on the GHCEA Registry website.

Our study systematically reviews the cost-per-DALY studies from 2000-2015, summarizing:

a) descriptive characteristics on study methodology: e.g., intervention type, country of study, study funder, study perspective,
b) methodological and reporting practices over time,
c) types of costs included in analyses,
d) the correlation between diseases researched and the burden of disease in different world regions

The number of published cost-per-DALY studies increased markedly after 2007.  Notably, 85 studies were published in 2015, compared with 46 in 2014.



Cost-per-DALY studies from Sub-Saharan Africa comprised the largest portion of published studies and the disease areas most commonly studied were communicable, maternal, neonatal, and nutritional disorders (67%), followed by non-communicable diseases (28%).  We also found that adherence to good practices for conducting and reporting cost-effectiveness analysis varied considerably. Studies mainly included formal healthcare sector costs but varied considerably in their inclusion of other cost components.  A large number of the studies in Sub-Saharan Africa addressed high-burden conditions such as HIV/AIDS, tuberculosis, neglected tropical diseases and malaria, and diarrhea, lower respiratory infections, meningitis, and other common infectious diseases.

Reference
[1] Neumann PJ, Thorat T, Zhong Y, Anderson J, Farquhar M, Salem M, et al. (2016) A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted. PLoS ONE 11(12) 2016.

By CEA Registry Team on 12/21/2016 8:58 AM
Once each week we highlight findings from recently published cost-effectiveness studies:
  • Universal approach to antenatal HIV testing is cost-effective: A study on the cost-effectiveness of HIV testing strategies for pregnant woman from both high and low HIV prevalence settings found that a universal instead of focused approach achieved better health outcomes and was cost-saving or cost-effective across a range of settings. (3)
  • CT scans for all anticoagulated patients with head injuries is not cost-effective: Selective use of CT scanning for those with evidence of traumatic brain injury is recommended in the UK and more cost-effective than providing CT scans for all anticoagulated patients with head injuries. (5)
  • Potential ART adherence monitoring interventions in Sub-Saharan Africa is potentially cost-effective: In situations where viral load monitoring may or may not be available, adherence monitoring-based interventions provide health benefits and are potentially cost-effective, depending on the intervention cost. (8)
  • The next generation nonavalent HPV vaccine may change the number of recommended cervical cancer screenings in developed countries: Cervical cancer screenings were still found to be cost-effective among women who receive the new human papillomavirus (HPV) vaccine, however the number of optical screening tests will vary across developed countries. (9)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published December 12-16, 2016.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Cichosz SL, Ehlers LH, Hejlesen O. Health effectiveness and cost-effectiveness of telehealthcare for heart failure: study protocol for a randomized controlled trial. Trials. 2016 Dec 12;17(1):590. PMID: 27955682.
 
2: Elbasha E, Greaves W, Roth D, Nwankwo C. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. J Viral Hepat. 2016 Dec 13. PMID: 27966249.
 

3: Ishikawa N, Dalal S, Johnson C, Hogan DR, Shimbo T, Shaffer N, Pendse RN, Lo YR, Ghidinelli MN, Baggaley R. Should HIV testing for all pregnant women continue? Cost-effectiveness of

universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings. J Int AIDS Soc. 2016  Dec 14;19(1):21212. PMID: 27978939.
 
4: Kornelsen JA, Barclay L, Grzybowski S, Gao Y. Rural health service planning: the need for a comprehensive approach to costing. Rural Remote Health. 2016 Oct-Dec;16(4):3604. PMID: 27978763.
 
5: Kuczawski M, Stevenson M, Goodacre S, Teare MD, Ramlakhan S, Morris F, Mason S. Should all anticoagulated patients with head injury receive a CT scan? Decision-analysis modelling of an observational cohort. BMJ Open. 2016 Dec 13;6(12):e013742. PMID: 27974370.
 
6: Meltzer ME, Congdon N, Kymes SM, Yan X, Lansingh VC, Sisay A, Müller A, Chan
VF, Jin L, Karumanchi SM, Guan C, Vuong Q, Rivera N, McCleod-Omawale J, He M. Cost and Expected Visual Effect of Interventions to Improve Follow-up After Cataract Surgery: Prospective Review of Early Cataract Outcomes and Grading (PRECOG) Study. JAMA Ophthalmol. 2016 Dec 15. PMID: 27978578.
 
7: Olfert JA, Penz ED, Manns BJ, Mishra EK, Davies HE, Miller RF, Luengo-Fernandez R, Gao S, Rahman NM. Cost-effectiveness of indwelling pleural catheter compared with talc in malignant pleural effusion. Respirology. 2016 Dec 16. PMID: 27983774.
 
8: Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Sow PS, Ehrenkranz P, Ford D, Mugurungi O, Apollo T, Murungu J, Bangsberg DR, Revill P. Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan  Africa. PLoS One. 2016 Dec 15;11(12):e0167654. PMID: 27977702.
 

9: Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K. Will cervical screeni

ng remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. Int J Cancer. 2016 Dec 15;139(12):2771-2780. PMID: 27541596.
 
10: Turner HC, Bettis AA, Chu BK, McFarland DA, Hooper PJ, Mante SD, Fitzpatrick C, Bradley MH. Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis. Clin Infect Dis. 2016 Dec 12. PMID: 27956460.
 
11: Wang Z, Chen Z, Wang X, Hao G, Ma L, Zhao X, Li Y, Zhang L, Zhu M. Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China. J Hypertens. 2016 Dec 12. PMID: 27977472.
By CEA Registry Team on 12/12/2016 1:52 PM
 Once each week we highlight findings from recently published cost-effectiveness studies:
 
  • Primary prophylaxis among patients with early-stage breast cancer or non-Hodgkin lymphoma (NHL) found to be cost-effective strategy: Primary prophylaxis with pegfilgrastim was found to be more cost-effective compared to other prophylaxis approaches in patients with stage II breast cancer or NHL in Belgium. (6)
  • Screening for ovarian cancer is both more effective and more expensive than not screening: Lifetime outcomes and cost-effectiveness of screening for ovarian cancer with multimodal screening in the UK was found to be worthwhile. (10)
  • Direct-acting anti-viral treatment in liver transplant candidates with Hepatitis C found to be cost-effective strategy: Deferring treatment for Hepatitis C until after liver transplant and maintaining access to the expanded pool of HCV(+) donors appears to be the most cost-effective strategy for well-compensated HCV-infected cirrhotics listed for liver transplantation. (17)
  •  Community-based care management for patients with chronic obstructive pulmonary disease (COPD) in Denmark more costly, but more effective: A new analysis revealed that while case management for patients with COPD was more expensive than usual care, a greater gain in health benefits was observed. The cost-effectiveness ratio observed exceeds thresholds set by NICE, but no formal CEA threshold values exist in Denmark. (19)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published December 5-9, 2016.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Cost-effectiveness of repairing versus replacing composite or amalgam restorations. Br Dent J. 2016 Dec 9;221(11):716. PMID: 27932813.
 
2: Ademi Z, Gloy V, Glinz D, Raatz H, Van Stiphout J, Bucher HC, Schwenkglenks M. Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective. Swiss Med Wkly. 2016 Dec 5;146:w14382.
PMID: 27922167.
 
3: Boccalini S, Bechini A, Gasparini R, Panatto D, Amicizia D, Bonanni P. Economic studies applied to vaccines against invasive diseases: an updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. Hum Vaccin Immunother. 2016 Dec 7:0. PMID:27925845.
 
4: Elser JL, Bigler LL, Anderson AM, Maki JL, Lein DH, Shwiff SA. The Economics of a Successful Raccoon Rabies Elimination Program on Long Island, New York. PLoS Negl Trop Dis. 2016 Dec 9;10(12):e0005062. PMID: 27935946.
 
5: Endo IC, Ziegelmann PK, Patel A. The economic promise of developing and implementing dengue vaccines: Evidence from a systematic review. Vaccine. 2016 Dec 7;34(50):6133-6147. PMID: 27810313.
 
6: Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. Pharmacoeconomics. 2016 Dec 7. PMID: 27928760.
 
7: Giordano A, Bonometti GP, Vanoglio F, Paneroni M, Bernocchi P, Comini L, Giordano A. Feasibility and cost-effectiveness of a multidisciplinary home-telehealth intervention programme to reduce falls among elderly discharged from hospital: study protocol for a randomized controlled trial. BMC Geriatr. 2016 Dec 7;16(1):209. PMID: 27923343.
 
8: Jenks M, Taylor M, Shore J. Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec 9. PMID: 27935333.
 
9: Jiang M, You JH. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Cardiovasc Drugs Ther. 2016 Dec 7. PMID: 27924429.
 
10: Kearns B, Chilcott J, Whyte S, Preston L, Sadler S. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Med. 2016 Dec 6;14(1):200. PMID: 27919292.
 
11: Kingsley J, Karanth S, Revere FL, Agrawal D. Cost Effectiveness of Screening Colonoscopy Depends on Adequate Bowel Preparation Rates - A Modeling Study. PLoS One. 2016 Dec 9;11(12):e0167452. PMID:
27936028.
 
12: Kolu P, Raitanen J, Puhkala J, Tuominen P, Husu P, Luoto R. Effectiveness and Cost-Effectiveness of a Cluster-Randomized Prenatal Lifestyle Counseling Trial: A Seven-Year Follow-Up. PLoS One. 2016 Dec 9;11(12):e0167759. PMID: 27936083.
 
13: Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clin Drug Investig. 2016 Dec 7. PMID: 27928739.
 
14: Luttjeboer J, Setiawan D, Cao Q, Cahh Daemen T, Postma MJ. Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands. Vaccine. 2016 Dec 7;34(50):6381-6387. PMID: 27816370.
 
15: Maurer KA, Chen HF, Wagner AL, Hegde ST, Patel T, Boulton ML, Hutton DW. Cost-effectiveness analysis of pneumococcal vaccination for infants in China. Vaccine. 2016 Dec 7;34(50):6343-6349.PMID: 27810315.
 
16: Misra UK, Mani VE, Kalita J. A Cost-Effective Approach to the Diagnosis and Management of Acute Infectious Encephalitis. Eur Neurol. 2016 Dec 8;77(1-2):66-74. PMID: 27924792.
 
17: Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC. Cost-Effectiveness of Direct-Acting Anti-viral Treatment in Hepatitis C-infected Liver Transplant Candidates with Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation. 2016 Dec 6. PMID:27926593.
 
18: Shiffman D, Arellano AR, Caulfield MP, Louie JZ, Bare LA, Devlin JJ, Melander O. Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. BMC Cardiovasc Disord. 2016 Dec 7;16(1):251. PMID: 27927162.
 
19: Sørensen SS, Pedersen KM, Weinreich UM, Ehlers L. Economic Evaluation of Community-Based Case Management of Patients Suffering From Chronic Obstructive Pulmonary Disease. Appl Health Econ Health Policy. 2016 Dec 7. PMID: 27928660.

20: Xu S, Immaneni S, Hazen GB, Silverberg JI, Paller AS, Lio PA. Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis. JAMA Pediatr. 2016 Dec 5:e163909. PMID: 27918774.

21: Zhao D, Gai Tobe R, Cui M, He J, Wu B. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine. 2016 Dec 7;34(50):6158-6165. PMID: 27838068.
By CEA Registry Team on 12/5/2016 4:12 PM

Once each week we highlight findings from recently published cost-effectiveness studies:

• Pneumococcal vaccine found to be cost-saving among infants: The newest pneumococcal vaccine (PHiD-CV) introduced in the UK national vaccination program was found to produce greater cost-savings and more health benefits compared to the PCV-13 pneumococcal vaccine. (2)
 
• Introduction of a new flu vaccine found to be beneficial: The Quadrivalent influenza vaccine (QIV) was projected to have greater health gains and cost-savings compared to the Trivalent influenza vaccine (TIV) in Germany. (3)
 
• HIV prevention strategies offer cost-effective alternative: Among HIV prevention strategies for men who have sex with men, preexposure prophylaxis (PrEP) and test-and-treat methods were found to be highly cost-effective relative to currently practiced methods. (4)
 
• Targeted lifestyle intervention valuable in preventing type 2 diabetes: An intervention focused on nutrition and physical activity was found to very cost-effective in preventing or delaying type 2 diabetes compared to no intervention in a Swedish community. (23)
 
See below for a full list of all cost-utility studies and selected reviews and editorials published November 28 to December 2, 2016.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. J Med Econ. 2016 Dec;19(12):1127-1134.
PMID: 27310712.
 
2: Delgleize E, Leeuwenkamp O, Theodorou E, Van de Velde N. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model. BMJ Open. 2016 Nov 30;6(11):e010776. PMID: 27903558.
 
3: Dolk C, Eichner M, Welte R, Anastassopoulou A, Van Bellinghen LA, Poulsen Nautrup B, Van Vlaenderen I, Schmidt-Ott R, Schwehm M, Postma M. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. Pharmacoeconomics. 2016 Dec;34(12):1299-1308. PMID: 27647004.
 
4: Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. Clin Infect Dis. 2016 Dec 1;63(11):1495-1504. PMID:27558571.
 
5: Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther. 2016 Dec 1. PMID: 27910116.
 
6: Eljamel MS, Mahboob SO. The effectiveness and cost-effectiveness of intraoperative imaging in high-grade glioma resection; a comparative review of intraoperative ALA, fluorescein, ultrasound and MRI. Photodiagnosis Photodyn Ther. 2016 Dec;16:35-43. PMID:27491856.
 
7: Evans M, Gundgaard J, Hansen BB. Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective. Diabetes Ther. 2016 Dec;7(4):809-823. PMID: 27553066.
 
8: Fisher M, Walker A, Falqués M, Moya M, Rance M, Taylor D, Lindner L. Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland. Eur J Health Econ. 2016 Dec;17(9):1091-1100. PMID: 26728984.
 
9: Gao LL, Basta M, Kanchwala SK, Serletti JM, Low DW, Wu LC. Cost-effectiveness  of microsurgical reconstruction for head and neck defects after oncologic resection. Head Neck. 2016 Nov 29. PMID: 27898195.
10: Gordon J, McEwan P, Hurst M, Puelles J. The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. Diabetes Ther. 2016 Dec;7(4):825-845. PMID:27787778.
 
11: Gordon J, McEwan P, Sabale U, Kartman B, Wolffenbuttel BH. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. J Med Econ. 2016 Dec;19(12):1167-1174. PMID: 27356188.
 
12: Gras A, Broughton J. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):771-779. PMID: 26750641.
 
13: Hager J, Henriksson M, Carlsson P, Länne T, Lundgren F. Revisiting the cost-effectiveness of screening 65-year-old men for abdominal aortic aneurysm based on data from an implemented screening programme. Int Angiol. 2016 Dec 1. PMID: 27905693.
 
14: Jalal H, O'Dell JR, Bridges SL Jr, Cofield S, Curtis JR, Mikuls TR, Moreland  LW, Michaud K. Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1751-1757. PMID:27015606.
 
15: Jeong K, Cairns J. Systematic review of health state utility values for economic evaluation of colorectal cancer. Health Econ Rev. 2016 Dec;6(1):36. PMID: 27541298; 
 
16: Kisiel JB, Konijeti GG, Piscitello AJ, Chandra T, Goss TF, Ahlquist DA, Farraye FA, Ananthakrishnan AN. Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2016 Dec;14(12):1778-1787.e8. PMID: 27464589.
 
17: Lester-Coll NH, Dosoretz AP, Magnuson WJ, Laurans MS, Chiang VL, Yu JB. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases. J Neurosurg. 2016 Dec;125(Suppl 1):18-25.  PMID: 27903191.
 
18: Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. J Med Econ. 2016 Dec 2:1-9. PMID: 27841717.
 
19: Luca NJ, Burnett HF, Ungar WJ, Moretti ME, Beukelman T, Feldman BM, Schwartz G, Bayoumi AM. Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1803-1811. PMID:27059807.
 
20: Mahon J, Claxton L, Wood H. Modelling the cost-effectiveness of human milk and breastfeeding in preterm infants in the United Kingdom. Health Econ Rev. 2016 Dec;6(1):54. PMID: 27909996.
 
21: Maru S, Byrnes JM, Carrington MJ, Stewart S, Scuffham PA. Long-term cost-effectiveness of home versus clinic-based management of chronic heart failure: the WHICH? study. J Med Econ. 2016 Dec 1:1-10. PMID: 27841726.
 
22: Murphy J, Gray A, Cooper C, Cooper D, Ramsay C, Carr A. Costs, quality of life and cost-effectiveness of arthroscopic and open repair for rotator cuff tears: an economic evaluation alongside the UKUFF trial. Bone Joint J. 2016 Dec;98-B(12):1648-1655. PMID: 27909127.
 
23: Neumann A, Lindholm L, Norberg M, Schoffer O, Klug SJ, Norström F. The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program. Eur J Health Econ. 2016 Dec 2. PMID: 27913943.
 
24: Pinyol C, Cepeda JM, Roldan I, Roldan V, Jimenez S, Gonzalez P, Soto J. A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation. Cardiol Ther. 2016 Dec;5(2):171-186. PMID: 27457613.
 
25: Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M, Lobo A. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2016 Dec;34(12):1241-1253. PMID: 27480631.
 
26: Salisbury AC, Li H, Vilain KR, Jaff MR, Schneider PA, Laird JR, Cohen DJ. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial. JACC Cardiovasc Interv. 2016 Nov 28;9(22):2343-2352. PMID: 27884360.
 
27: Silverstein A, Costas-Chavarri A, Gakwaya MR, Lule J, Mukhopadhyay S, Meara JG, Shrime MG. Laparoscopic Versus Open Cholecystectomy: A Cost-Effectiveness Analysis at Rwanda Military Hospital. World J Surg. 2016 Nov 30. PMID: 27905020.
 
28: Tinelli M, Ryan M, Bond C. What, who and when? Incorporating a discrete choice experiment into an economic evaluation. Health Econ Rev. 2016 Dec;6(1):31.PubMed PMID: 27472943; 
 
29: Virabhak S, Yasui K, Yamazaki K, Johnson S, Mitchell D, Yuen C, Samp JC, Igarashi A. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ. 2016 Dec;19(12):1144-1156. PMID: 27348464.
 
30: Wielage RC, Perk S, Campbell NL, Klein TM, Posta LM, Yuran T, Klein RW, Ng DB. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives. J Med Econ. 2016 Dec;19(12):1135-1143. PMID: 27326725.
 
31: Yan X, Gu X, Zhou L, Lin H, Wu B. Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. Clin Drug Investig. 2016 Dec; 36(12):1001-1010. PMID:27581246.
 
32: Zang X, Tang H, Min JE, Gu D, Montaner JS, Wu Z, Nosyk B. Cost-Effectiveness of the 'One4All' HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China. PLoS One. 2016 Nov PMID: 27893864.
 
33: Zhang P, Yang Y, Wen F, Wheeler J, Fu P, Li Q. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2016 Dec;31(12):1978-1985. PMID: 27118432.
By CEA Registry Team on 11/28/2016 4:26 PM

 Once each week we highlight findings from recently published cost-effectiveness studies:

Apixaban regarded as cost-effective treatment option for stroke prevention in Greece: Apixaban was found to be a cost-effective treatment option versus warfarin and aspirin for the prevention of stroke in patients with atrial fibrillation from a Greek healthcare payer perspective (2).
 
• Future prevalence and cost burden of Chronic Lymphocytic Leukemia (CLL) estimated to have large financial impact: The increased benefit of oral targeted therapies is projected to enhance CLL survivorship but higher costs can impose a substantial financial burden on both patients and payers in the U.S. (4).
 
• Cognitive screening tests for detecting dementia and mild cognitive impairment found to be cost-effective: Cognitive screening tests for use by General Practitioners considered a cost-effective strategy compared to standard of care in England (18).
 
See below for a full list of all cost-utility studies and selected reviews and editorials published November 21-25, 2016.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
 
1: Arefian H, Heublein S, Scherag A, Brunkhorst FM, Younis MZ, Moerer O, Fischer D, Hartmann M. Hospital-related cost of sepsis: A systematic review. J Infect. 2016 Nov 21. pii: S0163-4453(16)30288-2. PMID: 27884733.
 
2: Athanasakis K, Boubouchairopoulou N, Karampli E, Tarantilis F, Savvari P, Bilitou A, Kyriopoulos J. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. Am J Cardiovasc Drugs. 2016 Nov 23. PMID: 27882517.
 
3: Bozkaya D, Livingston T, Migliaccio-Walle K, Odom T. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2016 Nov 21:1-6. PMID:27822961.
 
4: Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2016 Nov 21:JCO2016682856. PMID: 27870563.
 
5: Chotai S, Parker SL, Sielatycki JA, Sivaganesan A, Kay HL, Wick JB, McGirt MJ, Devin CJ. Impact of old age on patient-report outcomes and cost utility for anterior cervical discectomy and fusion surgery for degenerative spine disease. Eur Spine J. 2016 Nov 24. PMID: 27885477.
 
6: Gama E, Were V, Ouma P, Desai M, Niessen L, Buff AM, Kariuki S. Large-scale implementation of disease control programmes: a cost-effectiveness analysis of long-lasting insecticide-treated bed net distribution channels in a malaria-endemic area of western Kenya-a study protocol. BMJ Open. 2016 Nov 21;6(11):e012776. PMID: 27872120.
 
7: Gu S, Zeng Y, Yu D, Hu X, Dong H. Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLoS One. 2016 Nov 22;11(11):e0167190. PMID: 27875596.
 
8: Hellard M, Pedrana A, Scott N. Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination? J Hepatol. 2016 Nov 21. PMID: 27884764.
 
9: Klebanoff MJ, Corey KE, Chhatwal J, Kaplan LM, Chung RT, Hur C. Bariatric Surgery for Nonalcoholic Steatohepatitis: A Clinical and Cost-Effectiveness Analysis. Hepatology. 2016 Nov 23. PMID: 27880977.
 
10: Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy. 2016 Nov 21. PMID: 27870079.
 
11: Malet-Larrea A, García-Cárdenas V, Sáez-Benito L, Benrimoj SI, Calvo B, Goyenechea E. Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):747-758. PMID: 27828725.
 
12: Maulsby C, Jain KM, Weir BW, Enobun B, Riordan M, Charles VE; RiC Intervention Team., Holtgrave DR. The Cost and Threshold Analysis of Retention in Care (RiC): A Multi-Site National HIV Care Program. AIDS Behav. 2016 Nov 21. PMID: 27873083.
 
13: Ong AA, Carroll WW, Nguyen SA, Gillespie MB. Cost-effectiveness of transfacial gland-preserving removal of parotid sialoliths. Laryngoscope. 2016 Nov 22. PMID: 27873327.
 
14: Patterson PD, Smith KJ, Hostler D. Cost-effectiveness of workplace wellness to prevent cardiovascular events among U.S. firefighters. BMC Cardiovasc Disord. 2016 Nov 21;16(1):229. PMID: 27871247.
 
15: Serra-Arbeloa P, Rabines-Juárez ÁO, Álvarez-Ruiz MS, Guillén-Grima F. Cost of cutaneous melanoma by tumor stage: A descriptive analysis. Actas Dermosifiliogr. 2016 Nov 22. pii: S0001-7310(16)30329-5.PubMed PMID: 27887672.
 
16: Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin. 2016 Nov 23:1-11. PMID: 27817216.
 
17: Sutherland CS, Stone CM, Steinmann P, Tanner M, Tediosi F. Seeing beyond 2020: an economic evaluation of contemporary and emerging strategies for elimination of Trypanosoma brucei gambiense. Lancet Glob Health. 2016 Nov 21. PMID: 27884709.
 
18: Tong T, Thokala P, McMillan B, Ghosh R, Brazier J. Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care. Int J Geriatr Psychiatry. 2016 Nov 22. PMID: 27874210.
 
19: Wera E, Mourits MC, Siko MM, Hogeveen H. Cost-Effectiveness of Mass Dog Vaccination Campaigns against Rabies in Flores Island, Indonesia. Transbound Emerg Dis. 2016 Nov 23. PMID: 27878980.
 
20: Winters D, Casten R, Rovner B, Murchison A, Leiby BE, Haller JA, Hark L, Weiss DM, Pizzi LT. Cost-Effectiveness of Behavior Activation Versus Supportive Therapy on Adherence to Eye Exams in Older African Americans With Diabetes. Am J  Med Qual. 2016 Nov 23. PMID: 27884979.
 
21: Yue WW, Li XL, Xu HX, Lu F, Sun LP, Guo LH, He YP, Wang D, Yin ZQ. Quality of Life and Cost-Effectiveness of Radiofrequency Ablation versus Open Surgery for Benign Thyroid Nodules: a retrospective cohort study. Sci Rep. 2016 Nov 24;6:37838. PMID: 27883069.

Please view the blog archive for earlier entries

Search This Blog

Labels

Blog Archive

Archive
<March 2017>
SunMonTueWedThuFriSat
2627281234
567891011
12131415161718
19202122232425
2627282930311
2345678
Monthly
March, 2017 (3)
February, 2017 (6)
January, 2017 (6)
December, 2016 (4)
November, 2016 (4)
October, 2016 (3)
September, 2016 (2)
August, 2016 (1)
June, 2016 (1)
May, 2016 (1)
February, 2016 (2)
November, 2015 (1)
September, 2015 (2)
August, 2015 (1)
July, 2015 (2)
June, 2015 (5)
May, 2015 (6)
April, 2015 (4)
March, 2015 (6)
February, 2015 (6)
January, 2015 (5)
December, 2014 (5)
November, 2014 (2)
October, 2014 (5)
September, 2014 (7)
August, 2014 (5)
July, 2014 (3)
June, 2014 (2)
May, 2014 (1)
April, 2014 (3)
March, 2014 (3)
February, 2014 (3)
November, 2013 (1)
October, 2013 (4)
September, 2013 (4)
August, 2013 (9)
July, 2013 (7)
June, 2013 (6)
May, 2013 (4)
April, 2013 (4)
March, 2013 (6)
February, 2013 (7)
January, 2013 (5)
December, 2012 (6)
November, 2012 (8)
October, 2012 (11)
September, 2012 (9)
August, 2012 (10)
July, 2012 (11)
June, 2012 (10)
May, 2012 (10)
April, 2012 (9)
March, 2012 (9)
February, 2012 (7)
January, 2012 (4)
December, 2011 (3)
November, 2011 (5)
October, 2011 (8)
September, 2011 (6)
August, 2011 (4)
July, 2011 (10)
June, 2011 (8)
May, 2011 (10)
April, 2011 (9)
March, 2011 (9)
February, 2011 (8)
January, 2011 (6)
December, 2010 (7)
November, 2010 (10)
October, 2010 (7)
September, 2010 (5)
August, 2010 (8)
July, 2010 (13)
June, 2010 (8)
May, 2010 (9)
April, 2010 (7)
March, 2010 (5)
February, 2010 (9)
January, 2010 (2)
August, 2009 (1)
May, 2009 (1)
April, 2009 (1)
March, 2009 (1)
November, 2008 (1)